Besivance - Powerfully breaks the chain in pathogens of greater concern 1-3
  • Powerful and effective treatment
    of the pathogens of greater concern1-3
  • Provides long-lasting tear concentrations4-6
  • The first and only topical ophthalmic chlorofluoroquinolone1
    • BESIVANCE® is a dual-halogenated
      fluoroquinolone that provides potent
      inhibition of bacterial DNA replication1
  • Request Samples
Prescription pad
Indication

Besivance® (besifloxacin ophthalmic suspension) 0.6%, is a quinolone antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans *, CDC coryneform group G, Corynebacterium pseudodiphtheriticum*, Corynebacterium striatum*, Haemophilus influenza, Moraxella catarrhalis*, Moraxella lacunata*, Pseudomonas aeruginosa *, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hominis*, Staphylococcus lugdunensis*, Staphylococcus warneri*, Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumoniae, Streptococcus salivarius*

*Efficacy for this organism was studied in fewer than 10 infections.

Besifloxacin

Besifloxacin is a dual halogenated
fluoroquinolone antibiotic that provides potent
inhibition of bacterial DNA replication.

Watch the video to the right to learn more »

Video thumbnail
Important Risk Information About BESIVANCE®
  • BESIVANCE® is for topical ophthalmic use only, and should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye.
  • As with other anti-infectives, prolonged use of BESIVANCE® may result in overgrowth of non-susceptible organisms, including fungi. If super-infection occurs, discontinue use and institute alternative therapy.
  • Patients should not wear contact lenses if they have signs or symptoms of bacterial conjunctivitis or during the course of therapy with BESIVANCE®
  • The most common adverse event reported in 2% of patients treated with BESIVANCE® was conjunctival redness. Other adverse events reported in patients receiving BESIVANCE® occurring in approximately 1-2% of patients included: blurred vision, eye pain, eye irritation, eye pruritus and headache.
  • BESIVANCE® is not intended to be administered systemically. Quinolones administered systemically have been associated with hypersensitivity reactions, even following a single dose. Patients should be advised to discontinue use immediately and contact their physician at the first sign of a rash or allergic reaction.
  • Safety and effectiveness in infants below one year of age have not been established.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch,
or call 1-800-FDA-1088.

Please click here to view the BESIVANCE® full prescribing information.


References: 1. BESIVANCE Prescribing Information, April 2009. 2. Tepedino ME, Heller WH, Usner DW, et al. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr Med Res Opin. 2009;25(5):1159-1169. 3. DeCory HH, Clinical Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% Against MRSA and MRSE, Annual Meeting of the Association for Research in Vision and Ophthalmology 2012; May 6-10, Fort Lauderdale, FL: 1 4. Data on File, CSR 424 2008, 424: 1-82, Bausch & Lomb Incorporated. 5. Proksch JW, Granvil CP, Siou-Mermet R, Comstock TL, Paterno MR, Ward KW. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans. J Ocul Pharmacol Ther. 2009;25(4):335-343. 6. Haas W, Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile. Clinical Ophthalmology 2011; 5: 1369-1379.

Legal Notice
©2014 Bausch & Lomb Incorporated. US/BES/13/0005 (1)

For product-related questions and concerns, call 1-800-323-0000
Bausch + Lomb Besivance besifloxacin opthalmic suspension, 0.6%

The information included on this website is intended for US healthcare professionals.

By clicking the button below, you acknowledge that you are a licensed US healthcare professional.

For eye care professionals
Close